BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16253023)

  • 1. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
    Cagle PT; Churg A
    Arch Pathol Lab Med; 2005 Nov; 129(11):1421-7. PubMed ID: 16253023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The separation of benign and malignant mesothelial proliferations.
    Churg A; Colby TV; Cagle P; Corson J; Gibbs AR; Gilks B; Grimes M; Hammar S; Roggli V; Travis WD
    Am J Surg Pathol; 2000 Sep; 24(9):1183-200. PubMed ID: 10976692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.
    Scurry J; Duggan MA
    J Clin Pathol; 1999 Jul; 52(7):535-7. PubMed ID: 10605410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
    Sington JD; Morris LS; Nicholson AG; Coleman N
    Histopathology; 2003 May; 42(5):498-502. PubMed ID: 12713628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-catenin expression in benign and malignant pleural disorders.
    Anani W; Bruggeman R; Zander DS
    Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. My approach to the diagnosis of mesothelial lesions.
    Butnor KJ
    J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
    Churg A; Sheffield BS; Galateau-Salle F
    Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Morphological diagnostics of malignant pleural mesothelioma].
    Junker K; Müller KM
    Pathologe; 2014 Nov; 35(6):586-90. PubMed ID: 25304423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].
    Krismann M; Thattamparambil P; Simon F; Johnen G
    Pathologe; 2006 Mar; 27(2):99-105. PubMed ID: 16435096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies.
    Allen TC
    Arch Pathol Lab Med; 2005 Nov; 129(11):1415-20. PubMed ID: 16253022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The separation of benign and malignant mesothelial proliferations.
    Churg A; Galateau-Salle F
    Arch Pathol Lab Med; 2012 Oct; 136(10):1217-26. PubMed ID: 23020727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
    Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
    Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach.
    Kradin RL; Mark EJ
    Semin Diagn Pathol; 2006 Feb; 23(1):4-14. PubMed ID: 17044190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computerized interactive morphometry. A study of malignant mesothelioma and mesothelial hyperplasia in pleural biopsy specimens.
    Marchevsky AM; Gil J; Caccamo D
    Arch Pathol Lab Med; 1985 Dec; 109(12):1102-5. PubMed ID: 3840984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Florid mesothelial hyperplasia of the tunica vaginalis mimicking malignant mesothelioma: a clinicopathologic study of 12 cases.
    Lee S; Illei PB; Han JS; Epstein JI
    Am J Surg Pathol; 2014 Jan; 38(1):54-9. PubMed ID: 24061516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Observation of the morphological genesis of pleural mesothelioma induced by asbestos in rats].
    Wang C; Luo S; Liu X
    Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):181-4. PubMed ID: 1452154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
    Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
    Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.